Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 20

Sort by

Sort Order Select

Meeting Abstracts

879-P: The Effects of the Combination of Dorzagliatin and Canagliflozin on Glucose Homeostasis in Mice

DONGNA HAN, TINGTING ZHANG, SHI MENG, LI CHEN, CHANGHONG LI

Diabetes 2024;73(Supplement_1):879-P

https://doi.org/10.2337/db24-879-P

Published: 14 June 2024

View article titled, 879-P: The Effects of the Combination of Dorzagliatin and Canagliflozin on Glucose Homeostasis in Mice

Meeting Abstracts

1887-LB: Effect of Dorzagliatin, a Dual-Acting Glucokinase Activator, on Insulin and Glucagon Secretion in Impaired and Normal Glucose Tolerance

ZHENGLI BAI, KE WANG, TIFFANY TSE LING YAU, EMILY W. POON, ANDREA LUK, RONALD C. MA, ALICE P. KONG, ELAINE CHOW, LI CHEN, JULIANA C. CHAN

Diabetes 2024;73(Supplement_1):1887-LB

https://doi.org/10.2337/db24-1887-LB

Published: 14 June 2024

View article titled, 1887-LB: Effect of Dorzagliatin, a Dual-Acting Glucokinase Activator, on Insulin and Glucagon Secretion in Impaired and Normal Glucose Tolerance

Meeting Abstracts

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial

MING LIU, WEIJUN GU, LI CHEN, YANBING LI, HONGYU KUANG, JIANLING DU, AGUSTINA ALVAREZ, FELIPE LAUAND, SR., ELISABETH SOUHAMI, JIEWEN ZHANG, WEIYA XU, QIN DU, YIMING MU

Diabetes 2024;73(Supplement_1):1869-LB

https://doi.org/10.2337/db24-1869-LB

Published: 14 June 2024

View article titled, 1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial

Meeting Abstracts

96-LB: Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

YUANHUI ZHANG, LINGGE FENG, LI CHEN, DONGYANG LIU

Diabetes 2023;72(Supplement_1):96-LB

https://doi.org/10.2337/db23-96-LB

Published: 20 June 2023

View article titled, 96-LB: Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

Meeting Abstracts

293-LB: Dorzagliatin, a Glucokinase Activator, Restores Glucose-Sensing in Type 2 Diabetic Human Islets

JEFFEREY ROMAN, QIUSHA ZHU, YUE YUAN, CHANGHONG LI, LI CHEN, NICOLAI M. DOLIBA

Diabetes 2023;72(Supplement_1):293-LB

https://doi.org/10.2337/db23-293-LB

Published: 20 June 2023

View article titled, 293-LB: Dorzagliatin, a Glucokinase Activator, Restores Glucose-Sensing in Type 2 Diabetic Human Islets

Meeting Abstracts

208-LB: Plasma Lipidomics Reveals Sex-Specific Associations with? Brown Adipose Tissue in Asian Children

MYA THWAY TINT, LI CHEN, NARASIMHAN KOTHANDARAMAN, MELVIN K. LEOW, BHANU PRAKASH KN, FABIAN YAP, YUNG SENG LEE, ELIZABETH H. THAM, YAP-SENG CHONG, MARIELLE V FORTIER, KEITH GODFREY, MARKUS WENK, JOHAN ERIKSSON

Diabetes 2023;72(Supplement_1):208-LB

https://doi.org/10.2337/db23-208-LB

Published: 20 June 2023

View article titled, 208-LB: Plasma Lipidomics Reveals Sex-Specific Associations with? Brown Adipose Tissue in Asian Children

Meeting Abstracts

247-LB: Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

LI CHEN, JIANGXIA NI, LINGGE FENG, XUEXIN ZHANG, QIUYAN WANG, YELIN CHEN

Diabetes 2023;72(Supplement_1):247-LB

https://doi.org/10.2337/db23-247-LB

Published: 20 June 2023

View article titled, 247-LB: Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

Journal Articles

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Elaine Chow, Ke Wang, Cadmon K.P. Lim, Sandra T.F. Tsoi, Baoqi Fan, Emily Poon, Andrea O.Y. Luk, Ronald C.W. Ma, Ele Ferrannini, Andrea Mari, Li Chen, Juliana C.N. Chan

Diabetes 2023;72(2):299–308

https://doi.org/10.2337/db22-0708

Published: 28 October 2022

View article titled, Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Meeting Abstracts

117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient—A Post Hoc Analysis of Dorzagliatin

LINGGE FENG, QUANLE GUO, CHUNXIANG CHEN, XIANG LIU, LI CHEN, WENYING YANG

Diabetes 2022;71(Supplement_1):117-LB

https://doi.org/10.2337/db22-117-LB

Published: 01 June 2022

View article titled, 117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient—A Post Hoc Analysis of Dorzagliatin

Meeting Abstracts

261-OR: Dorzagliatin, a Dual-Acting Glucokinase Activator. Improves Insulin Secretion and Glucose Sensitivity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY)

ELAINE CHOW, KE WANG, CADMON K.P. LIM, SANDRA TSOI, BAOQI FAN, ANDREA LUK, RONALD C. MA, ELE FERRANNINI, ANDREA MARI, LI CHEN, JULIANA C. CHAN

Diabetes 2022;71(Supplement_1):261-OR

https://doi.org/10.2337/db22-261-OR

Published: 01 June 2022

View article titled, 261-OR: Dorzagliatin, a Dual-Acting Glucokinase Activator. Improves Insulin Secretion and Glucose Sensitivity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY)

Meeting Abstracts

235-OR: Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control with Good Safety Profiles in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED)

LI CHEN, YI ZHANG, DALONG ZHU

Diabetes 2021;70(Supplement_1):235-OR

https://doi.org/10.2337/db21-235-OR

Published: 01 June 2021

View article titled, 235-OR: Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control with Good Safety Profiles in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED)

Meeting Abstracts

763-P: Dorzagliatin Add-On to Metformin Achieved Sustained Efficacy and Good Safety Profiles in T2D Patients in a 52-Week Phase 3 Trial (DAWN)

LI CHEN, YI ZHANG, WENYING YANG

Diabetes 2021;70(Supplement_1):763-P

https://doi.org/10.2337/db21-763-P

Published: 01 June 2021

View article titled, 763-P: Dorzagliatin Add-On to Metformin Achieved Sustained Efficacy and Good Safety Profiles in T2D Patients in a 52-Week Phase 3 Trial (DAWN)

Meeting Abstracts

117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function

LI CHEN, JIAYI ZHANG, RONG YANG, LINGGE FENG, HUA MEDICINE

Diabetes 2021;70(Supplement_1):117-LB

https://doi.org/10.2337/db21-117-LB

Published: 01 June 2021

View article titled, 117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function

Journal Articles

TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model

Sha Sha, James A. Pearson, Jian Peng, Youjia Hu, Juan Huang, Yanpeng Xing, Luyao Zhang, Ying Zhu, Hongyu Zhao, F. Susan Wong, Li Chen, Li Wen

Diabetes 2021;70(2):504–515

https://doi.org/10.2337/db20-0373

Published: 05 November 2020

View article titled, TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model

Meeting Abstracts

182-OR: A Novel Dual-Acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients after 24 Weeks of Treatment in a Phase III Monotherapy Trial

DALONG ZHU, YI ZHANG, LI CHEN

Diabetes 2020;69(Supplement_1):182-OR

https://doi.org/10.2337/db20-182-OR

Published: 01 June 2020

View article titled, 182-OR: A Novel Dual-Acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients after 24 Weeks of Treatment in a Phase III Monotherapy Trial

Meeting Abstracts

1151-P: Dorzagliatin Differentiates from Early Generation of Glucokinase Activators: An Enzyme Kinetics Study

LI CHEN, YONGQIANG SHAN, XIAOWEI JIN, XIAOBING LV

Diabetes 2019;68(Supplement_1):1151-P

https://doi.org/10.2337/db19-1151-P

Published: 01 June 2019

View article titled, 1151-P: Dorzagliatin Differentiates from Early Generation of Glucokinase Activators: An Enzyme Kinetics Study

Meeting Abstracts

1158-P: Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

LI CHEN, LINGGE FENG, CUI TANG, YI ZHANG

Diabetes 2019;68(Supplement_1):1158-P

https://doi.org/10.2337/db19-1158-P

Published: 01 June 2019

View article titled, 1158-P: Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

Meeting Abstracts

Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator Dorzagliatin (HMS5552)—Twelve Weeks Treatment in T2D Patients in China

DALONG ZHU, YU ZHAO, CUI TANG, SR., HU TIANXIN, YONG-GUO LI, GUIYU ZHAO, XINGHUA HOU, SR., YI ZHANG, LI CHEN, HMM0201 STUDY GROUP

Diabetes 2018;67(Supplement_1):1201-P

https://doi.org/10.2337/db18-1201-P

Published: 01 July 2018

View article titled, Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator Dorzagliatin (HMS5552)—Twelve Weeks Treatment in T2D Patients in China

Meeting Abstracts

No Drug–Drug Interaction between Dorzagliatin and Metformin in Type 2 Diabetes Patients

LI CHEN, GUIYU ZHAO, SHUANG REN, YI ZHANG, DANIEL DU

Diabetes 2018;67(Supplement_1):2310-PUB

https://doi.org/10.2337/db18-2310-PUB

Published: 01 July 2018

View article titled, No Drug–Drug Interaction between Dorzagliatin and Metformin in Type 2 Diabetes Patients

Journal Articles

Activation of the AMPK-FOXO3 Pathway Reduces Fatty Acid–Induced Increase in Intracellular Reactive Oxygen Species by Upregulating Thioredoxin

Xiao-Nan Li, Jun Song, Lin Zhang, Scott A. LeMaire, Xiaoyang Hou, Cheng Zhang, Joseph S. Coselli, Li Chen, Xing Li Wang, Yun Zhang, Ying H. Shen

Diabetes 2009;58(10):2246–2257

https://doi.org/10.2337/db08-1512

Published: 10 July 2009

View article titled, Activation of the AMPK-FOXO3 Pathway Reduces Fatty Acid–Induced Increase in Intracellular Reactive Oxygen Species by Upregulating Thioredoxin

NARROW

879-P: The Effects of the Combination of Dorzagliatin and Canagliflozin on Glucose Homeostasis in Mice

1887-LB: Effect of Dorzagliatin, a Dual-Acting Glucokinase Activator, on Insulin and Glucagon Secretion in Impaired and Normal Glucose Tolerance

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial

96-LB: Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

293-LB: Dorzagliatin, a Glucokinase Activator, Restores Glucose-Sensing in Type 2 Diabetic Human Islets

208-LB: Plasma Lipidomics Reveals Sex-Specific Associations with? Brown Adipose Tissue in Asian Children

247-LB: Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient—A Post Hoc Analysis of Dorzagliatin

261-OR: Dorzagliatin, a Dual-Acting Glucokinase Activator. Improves Insulin Secretion and Glucose Sensitivity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY)

235-OR: Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control with Good Safety Profiles in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED)

763-P: Dorzagliatin Add-On to Metformin Achieved Sustained Efficacy and Good Safety Profiles in T2D Patients in a 52-Week Phase 3 Trial (DAWN)

117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function

TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model

182-OR: A Novel Dual-Acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients after 24 Weeks of Treatment in a Phase III Monotherapy Trial

1151-P: Dorzagliatin Differentiates from Early Generation of Glucokinase Activators: An Enzyme Kinetics Study

1158-P: Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator Dorzagliatin (HMS5552)—Twelve Weeks Treatment in T2D Patients in China

No Drug–Drug Interaction between Dorzagliatin and Metformin in Type 2 Diabetes Patients

Activation of the AMPK-FOXO3 Pathway Reduces Fatty Acid–Induced Increase in Intracellular Reactive Oxygen Species by Upregulating Thioredoxin

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only